- Metabolomic Biomarkers
- Proteomic Biomarkers
- Genomic Biomarkers
- Imaging Biomarkers
- Others
Neurological Biomarkers Market size was valued at USD 7 billion in 2022 and is poised to grow at a CAGR of 12.9% from 2023-2029. The global neurological biomarkers market is anticipated to record fast growth with the current neurological disorder conditions all across the world. A huge percentage of people are affected by neurological disorders and consequently causing major disabilities around the world. Because of the increasing cases of neurological disorders, demand for biomarkers is increased for measuring biological states. These biomarkers are also utilized for indication of biological and pathogenic process in terms of healing intervention. They are also used in combination to know the illness state of the person. Biomarkers are also used for those who are suffering from acute ischemic stroke, subarachnoid hemorrhage, and brain injury and intracerebral hemorrhage. The recovery of the patients is totally depending on their mitigation. In such type of situation, a delay can be there in proper examination of the patients due to the complexities. This situation calls for the use of biomarkers and promotes the biomarkers market. The research examines COVID-19 in light of changes in consumer behaviour and demand, purchasing patterns, supply chain re-routing, market dynamics, and government involvement. The revised report considers the influence of COVID-19 on the market and includes insights, analysis, projections, and predictions.
Global Neurological Biomarkers Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
12.9%
Largest Market
North America
Fastest Growing Market
Europe
Neurological Biomarkers Market Dynamics
The global neurological biomarkers market is expected to witness a rapid growth with the prevailing neurological disorder cases all over the world. A major percentage of world population is affected by neurological disorders; this in turn is causing major disabilities globally. Due to the high incidence of neurological disorders, there is the need for biomarkers as biomarkers measure biological states and are used for indication of both pathogenic as well as normal biological process in terms of therapeutic intervention. Biomarkers can also be utilized in combination for accessing the state of the disease of an individual. Urge in research proposals enables neurological biomarkers market to remain active. Increasing demand for personalized medicine to treat neurological disorders also boom the market growth. Another market driving factor is growing demand for non-invasive diagnostic methods for Parkinson's and Alzheimer's. Increasing demand for genomics biomarker will also impel the market growth. On the other hand, strict government rules will hinder the market growth. Emerging legal problems with early identification of Alzheimer's and Parkinson's illnesses can also be a restricting factor for the market growth.
North-America got significant share
Neurological Biomarkers Market Regional Analysis
Because of the several remarkable players operating in the North America, this region is anticipated to record a huge market share as compared to other regions. Another crucial reason behind booming the market in this region is several research and development projects are carried out in different areas of this region. Academic universities also got enough fund offered by the government for undertaking research. Asia Pacific comes on second number, which also witnesses the huge market revenue share due to the huge population and growing incidental cases of neurological abnormalities in the region. A few other market growing factors in this region are increasing numbers of aged population and entry of new key players in the market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The neurological biomarkers market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Neurological Biomarkers Market Segmentation
By Type
By Application
- Parkinson's Disease
- Multiple Sclerosis
- Alzheimer's Disease
- Autism Spectrum Disorders
- Others
By End User
- Clinical Diagnostic Centers
- Hospital Laboratories
- Research Organizations
- Others
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East and Africa
Frequently Asked Questions
The neurological biomarkers market size was valued at USD 7 billion in 2022
The neurological biomarkers market key players are Abbott Laboratories, Myriad Rbm, Inc, Athena Diagnostics, Immunarray Pvt. Ltd, Acumen Pharmaceuticals Inc, Banyan Biomarkers Inc
Increasing Product Launches and Approvals
| 1.Executive Summary |
| 2.Global Neurological Biomarkers Market Introduction |
| 2.1.Global Neurological Biomarkers Market - Taxonomy |
| 2.2.Global Neurological Biomarkers Market - Definitions |
| 2.2.1.Type |
| 2.2.2.Application |
| 2.2.3.End User |
| 2.2.4.Region |
| 3.Global Neurological Biomarkers Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Neurological Biomarkers Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Neurological Biomarkers Market By Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Metabolomic Biomarkers |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Proteomic Biomarkers |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Genomic Biomarkers |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Imaging Biomarkers |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Neurological Biomarkers Market By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Parkinson's Disease |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Multiple Sclerosis |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Alzheimer's Disease |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Autism Spectrum Disorders |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Others |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.Global Neurological Biomarkers Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Clinical Diagnostic Centers |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Hospital Laboratories |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Research Organizations |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Neurological Biomarkers Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Metabolomic Biomarkers |
| 9.1.2.Proteomic Biomarkers |
| 9.1.3.Genomic Biomarkers |
| 9.1.4.Imaging Biomarkers |
| 9.1.5.Others |
| 9.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Parkinson's Disease |
| 9.2.2.Multiple Sclerosis |
| 9.2.3.Alzheimer's Disease |
| 9.2.4.Autism Spectrum Disorders |
| 9.2.5.Others |
| 9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Clinical Diagnostic Centers |
| 9.3.2.Hospital Laboratories |
| 9.3.3.Research Organizations |
| 9.3.4.Others |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Metabolomic Biomarkers |
| 10.1.2.Proteomic Biomarkers |
| 10.1.3.Genomic Biomarkers |
| 10.1.4.Imaging Biomarkers |
| 10.1.5.Others |
| 10.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Parkinson's Disease |
| 10.2.2.Multiple Sclerosis |
| 10.2.3.Alzheimer's Disease |
| 10.2.4.Autism Spectrum Disorders |
| 10.2.5.Others |
| 10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Clinical Diagnostic Centers |
| 10.3.2.Hospital Laboratories |
| 10.3.3.Research Organizations |
| 10.3.4.Others |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 10.4.6.Rest of EU |
| 11.Asia Pacific (APAC) Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Metabolomic Biomarkers |
| 11.1.2.Proteomic Biomarkers |
| 11.1.3.Genomic Biomarkers |
| 11.1.4.Imaging Biomarkers |
| 11.1.5.Others |
| 11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Parkinson's Disease |
| 11.2.2.Multiple Sclerosis |
| 11.2.3.Alzheimer's Disease |
| 11.2.4.Autism Spectrum Disorders |
| 11.2.5.Others |
| 11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Clinical Diagnostic Centers |
| 11.3.2.Hospital Laboratories |
| 11.3.3.Research Organizations |
| 11.3.4.Others |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Metabolomic Biomarkers |
| 12.1.2.Proteomic Biomarkers |
| 12.1.3.Genomic Biomarkers |
| 12.1.4.Imaging Biomarkers |
| 12.1.5.Others |
| 12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Parkinson's Disease |
| 12.2.2.Multiple Sclerosis |
| 12.2.3.Alzheimer's Disease |
| 12.2.4.Autism Spectrum Disorders |
| 12.2.5.Others |
| 12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Clinical Diagnostic Centers |
| 12.3.2.Hospital Laboratories |
| 12.3.3.Research Organizations |
| 12.3.4.Others |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Neurological Biomarkers Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Metabolomic Biomarkers |
| 13.1.2.Proteomic Biomarkers |
| 13.1.3.Genomic Biomarkers |
| 13.1.4.Imaging Biomarkers |
| 13.1.5.Others |
| 13.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Parkinson's Disease |
| 13.2.2.Multiple Sclerosis |
| 13.2.3.Alzheimer's Disease |
| 13.2.4.Autism Spectrum Disorders |
| 13.2.5.Others |
| 13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Clinical Diagnostic Centers |
| 13.3.2.Hospital Laboratories |
| 13.3.3.Research Organizations |
| 13.3.4.Others |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Abbott Laboratories |
| 14.2.2.Myriad Rbm, Inc |
| 14.2.3.Athena Diagnostics |
| 14.2.4.Immunarray Pvt. Ltd |
| 14.2.5.Acumen Pharmaceuticals Inc |
| 14.2.6.Banyan Biomarkers Inc |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Abbott Laboratories
- Myriad Rbm, Inc
- Athena Diagnostics
- Immunarray Pvt. Ltd
- Acumen Pharmaceuticals Inc
- Banyan Biomarkers Inc